EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)Multizentrische StudieRandomisierte kontrollierte StudieÄquivalenzstudieOpen Access

Aspirin Discontinuation at 24 to 28 Weeks’ Gestation in Pregnancies at High Risk of Preterm Preeclampsia

Manel Mendoza, Erika Bonacina, Pablo Garcia-Manau, Monica López, Sara Caamiña, Àngels Vives, Eva Lopez-Quesada, Marta Ricart, Anna Maroto, Laura de Mingo, Elena Pintado, Roser Ferrer-Costa und 16 weitere

JAMA · 21.02.2023 · 329 (7) · 542

DOI: 10.1001/jama.2023.0691 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift JAMA, erschienen am 21.02.2023. Verfasst von Manel Mendoza und 27 weiteren Autor:innen. Beteiligte Einrichtung: Maternal Fetal Medicine Unit, Department of Obstetrics, Vall d'Hebron Barcelona Hospital Campus, Universitat Autònoma de Barcelona, Barcelona, Spain. Hauptthemen laut MEDLINE: Aspirin, Pre-Eclampsia, Premature Birth, Withholding Treatment. Die Arbeit wurde bisher 57-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance Aspirin reduces the incidence of preterm preeclampsia by 62% in pregnant individuals at high risk of preeclampsia. However, aspirin might be associated with an increased risk of peripartum bleeding, which could be mitigated by discontinuing aspirin before term (37 weeks of gestation) and by an accurate selection of individuals at higher risk of preeclampsia in the first trimester of pregnancy.

Objective

To determine whether aspirin discontinuation in pregnant individuals with normal soluble fms-like tyrosine kinase–1 to placental growth factor (sFlt-1:PlGF) ratio between 24 and 28 weeks of gestation was noninferior to aspirin continuation to prevent preterm preeclampsia. Design, Setting, and Participants Multicenter, open-label, randomized, phase 3, noninferiority trial conducted in 9 maternity hospitals across Spain. Pregnant individuals (n = 968) at high risk of preeclampsia during the first-trimester screening and an sFlt-1:PlGF ratio of 38 or less at 24 to 28 weeks of gestation were recruited between August 20, 2019, and September 15, 2021; of those, 936 were analyzed (intervention: n = 473; control: n = 463). Follow-up was until delivery for all participants.

Interventions

Enrolled patients were randomly assigned in a 1:1 ratio to aspirin discontinuation (intervention group) or aspirin continuation until 36 weeks of gestation (control group). Main Outcomes and Measures Noninferiority was met if the higher 95% CI for the difference in preterm preeclampsia incidences between groups was less than 1.9%.

Results

Among the 936 participants, the mean (SD) age was 32.4 (5.8) years; 3.4% were Black and 93% were White. The incidence of preterm preeclampsia was 1.48% (7/473) in the intervention group and 1.73% (8/463) in the control group (absolute difference, −0.25% [95% CI, −1.86% to 1.36%]), indicating noninferiority. Conclusions and Relevance Aspirin discontinuation at 24 to 28 weeks of gestation was noninferior to aspirin continuation for preventing preterm preeclampsia in pregnant individuals at high risk of preeclampsia and a normal sFlt-1:PlGF ratio. Trial Registration ClinicalTrials.gov Identifier: NCT03741179 and ClinicalTrialsRegister.eu Identifier: 2018-000811-26

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AspirinPre-EclampsiaPremature BirthWithholding TreatmentAdultFemaleHumansInfant, NewbornPregnancyBiomarkersHemorrhagePeripartum PeriodPlacenta Growth FactorPregnancy ComplicationsPregnancy Trimester, FirstVascular Endothelial Growth Factor Receptor-1

Substanzen

AspirinBiomarkersFLT1 protein, humanPGF protein, humanPlacenta Growth FactorVascular Endothelial Growth Factor Receptor-1

Autor:innen und Institutionen

  • Maternal Fetal Medicine Unit, Department of Obstetrics, Vall d'Hebron Barcelona Hospital Campus, Universitat Autònoma de Barcelona, Barcelona, Spain.
  • Department of Obstetrics, Hospital Universitari de Tarragona Joan XXIII, Tarragona, Spain.
  • Department of Obstetrics, Hospital Universitario Nuestra Señora de Candelaria, Santa Cruz de Tenerife, Spain.
  • Department of Obstetrics, Consorci Sanitari de Terrassa, Terrassa, Spain.
  • Department of Obstetrics, Hospital Universitari Mútua Terrassa, Terrassa, Spain.
  • Department of Obstetrics, Hospital Universitari Germans Trias i Pujol, Badalona, Spain.

Zitieren

APA

Mendoza, M., Bonacina, E., Garcia-Manau, P., López, M., Caamiña, S., Vives, À., Lopez-Quesada, E., Ricart, M., Maroto, A., de Mingo, L., Pintado, E., Ferrer-Costa, R., Martin, L., Rodríguez-Zurita, A., Garcia, E., Pallarols, M., Vidal-Sagnier, L., Teixidor, M., Orizales-Lago, C., …, & Suy, A. (2023). Aspirin Discontinuation at 24 to 28 Weeks’ Gestation in Pregnancies at High Risk of Preterm Preeclampsia. JAMA, 329(7), 542. https://doi.org/10.1001/jama.2023.0691

Vancouver

Mendoza M, Bonacina E, Garcia-Manau P, López M, Caamiña S, Vives À, et al. Aspirin Discontinuation at 24 to 28 Weeks’ Gestation in Pregnancies at High Risk of Preterm Preeclampsia. JAMA. 2023;329(7):542. doi:10.1001/jama.2023.0691

BibTeX
@article{Mendoza2023,
  author = {Mendoza, Manel and Bonacina, Erika and Garcia-Manau, Pablo and López, Monica and Caamiña, Sara and Vives, Àngels and Lopez-Quesada, Eva and Ricart, Marta and Maroto, Anna and de Mingo, Laura and Pintado, Elena and Ferrer-Costa, Roser and Martin, Lourdes and Rodríguez-Zurita, Alicia and Garcia, Esperanza and Pallarols, Mar and Vidal-Sagnier, Laia and Teixidor, Mireia and Orizales-Lago, Carmen and Pérez-Gomez, Adela and Ocaña, Vanesa and Puerto, Linda and Millán, Pilar and Alsius, Mercè and Diaz, Sonia and Maiz, Nerea and Carreras, Elena and Suy, Anna},
  title = {Aspirin Discontinuation at 24 to 28 Weeks’ Gestation in Pregnancies at High Risk of Preterm Preeclampsia},
  journal = {JAMA},
  year = {2023},
  volume = {329},
  number = {7},
  pages = {542},
  doi = {10.1001/jama.2023.0691}
}
Kostenlos starten →